Groundbreaking emergency
treatment for vasospasm & stroke.
Two-minute non-invasive
neuro stimulation treatment.
Patents issued in China, Europe,
and the United States.
CEREFAST controls cerebral vasodilation
and cerebral diffusion.
CAUTION – Investigational device. Not yet approved by US FDA for sale. Limited by United States law to investigational use.
Click on the video for a 2-minute overview of VACERE’s product and technology
A Groundbreaking
Emergency Treatment
for Stroke & Vasospasm
- Easy, non-invasive, neuro stimulation treatment.
- Relaxes cerebral arteries, allowing superior blood perfusion.
- Just one, 2-minute stimulation.
Our Leadership Team
Jeffrey Lietzke
CEO
20 years of medtech founding, commercialization, and exit experience.
Emilio Sacristan, PhD
PhD Chief Science Officer, Co-Founder and Director
Co-inventor of the CEREFAST.
Stephanie Harrington, MS
Chief Clinical and Regulatory Officer
20 years of experience in the medical device industry.
Guy Jean L. Savoir
Director
Businessman, entrepreneur and investor in the pharmaceutical and health-care industries.
Dr. John Andrefsky
Clinical Advisory Board
Vascular Neurologist at University Hospitals. Fellowship-trained in neurocritical care, Cleveland Clinic.
Pre-clinical &
Clinical Testing
- Completed healthy human subjects trial establishing safety, tolerability, and dose response.
- Clinical data in cerebral vasospasm patients showed a reduction of death-and-disability rates from 50% to 0% in a six-subject study when used to reverse vasospasm in the Neuro-ICU.
- 10 peer-reviewed scientific papers published to date.
Increase in brain perfusion index after one stimulation in blue; and after two stimulations 120 minutes apart in red.
Approach to Market
Peer-Reviewed Publications
- Facial nerve stimulation as a future treatment for ischemic stroke
- Effects of Noninvasive Facial Nerve Stimulation in the Dog Middle Cerebral Artery Occlusion Model of Ischemic Stroke
- Restored Brain Perfusion after Non-Invasive Stimulation of the Facial Nerve in a Canine Stroke Model
- Effect of pulsed magnetic stimulation of the facial nerve on cerebral blood flow
Vasospasm
Reference Center
- Vasospasm and Delayed Consequences
- Vasospasm: Types, Causes & Symptoms
- Cerebral Vasospasm After Subarachnoid Hemorrhage
- Cerebral Vasospasm Following Subarachnoid Hemorrhage
- Utility of transcranial Doppler ultrasound for the integrative assessment of cerebrovascular function
- Treatment Options for Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage
- Cerebral Vasospasm in Traumatic Brain Injury
Groundbreaking emergency
treatment for vasospasm & stroke.
Two-minute non-invasive
magnetic stimulation treatment.
US FDA Humanitarian Use Designation
confirmed for vasospasm.
Testing device eggectiveness
against migraines.
CAUTION – Investigational device. Not yet approved by US FDA for sale. Limited by United States law to investigational use.
Click on the video for a 2-minute overview of VACERE’s product and technology
A groundbreaking emergency treatment for stroke & vasospasm
- Easy, non-invasive, neuro stimulation treatment.
- Relaxes cerebral arteries, allowing superior blood perfusion.
- Just one, 2-minute stimulation.
Our Leadership Team
Jeffrey Lietzke
CEO
20 years of medtech founding, commercialization, and exit experience.
Emilio Sacristan, PhD
PhD Chief Science Officer, Co-Founder and Director
Co-inventor of the CEREFAST.
Stephanie Harrington, MS
Chief Clinical and Regulatory Officer
20 years of experience in the medical device industry.
Guy Jean L. Savoir
Director
Businessman, entrepreneur and investor in the pharmaceutical and health-care industries.
Dr. John Andrefsky
Clinical Advisory Board
Vascular Neurologist at University Hospitals. Fellowship-trained in neurocritical care, Cleveland Clinic.
Pre-clinical & Clinical Testing
- Completed healthy human subjects trial establishing safety, tolerability, and dose response.
- Clinical data in cerebral vasospasm patients showed a reduction of death-and-disability rates from 50% to 0% in a six-subject study when used to reverse vasospasm in the Neuro-ICU.
- 10 peer-reviewed scientific papers published to date.
Increase in brain perfusion index after one stimulation in blue; and after two stimulations 120 minutes apart in red.
Approach to Market
Peer-Reviewed Publications
- Facial nerve stimulation as a future treatment for ischemic stroke
- Effects of Noninvasive Facial Nerve Stimulation in the Dog Middle Cerebral Artery Occlusion Model of Ischemic Stroke
- Restored Brain Perfusion after Non-Invasive Stimulation of the Facial Nerve in a Canine Stroke Model
- Effect of pulsed magnetic stimulation of the facial nerve on cerebral blood flow
Vasospasm Reference Center
- Vasospasm and Delayed Consequences
- Vasospasm: Types, Causes & Symptoms
- Cerebral Vasospasm After Subarachnoid Hemorrhage
- Cerebral Vasospasm Following Subarachnoid Hemorrhage
- Utility of transcranial Doppler ultrasound for the integrative assessment of cerebrovascular function
- Treatment Options for Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage
- Cerebral Vasospasm in Traumatic Brain Injury
Groundbreaking emergency
treatment for vasospasm & stroke.
Two-minute non-invasive
neuro stimulation treatment.
Patents issued in China, Europe,
and the United States.
CEREFAST controls cerebral vasodilation
and cerebral diffusion.
CAUTION – Investigational device. Not yet approved by US FDA for sale. Limited by United States law to investigational use.
Click on the video for a 2-minute overview of VACERE’s product and technology
A groundbreaking emergency treatment for stroke & vasospasm
- Easy, non-invasive, magnetic stimulation treatment
- Relaxes cerebral arteries, allowing superior blood perfusion
- Just one, 2-minute stimulation
Our Leadership Team
Jeffrey Lietzke
CEO
20 years of medtech founding, commercialization, and exit experience.
Emilio Sacristan, PhD
PhD Chief Science Officer, Co-Founder and Director
Co-inventor of the CEREFAST.
Stephanie Harrington, MS
Chief Clinical and Regulatory Officer
20 years of experience in the medical device industry.
Guy Jean L. Savoir
Director
Businessman, entrepreneur and investor in the pharmaceutical and health-care industries.
Dr. John Andrefsky
Clinical Advisory Board
Vascular Neurologist at University Hospitals. Fellowship-trained in neurocritical care, Clevland Clinic.
Pre-clinical & Clinical Testing
- Completed healthy human subjects trial establishing safety, tolerability, and dose response.
- Clinical data in cerebral vasospasm patients showed a reduction of death-and-disability rates from 50% to 0% in a six-subject study when used to reverse vasospasm in the Neuro-ICU.
- 10 peer-reviewed scientific papers published to date.
Increase in brain perfusion index after one stimulation in blue; and after two stimulations 120 minutes apart in red.
Approach to Market
Peer-Reviewed Publications
- Facial nerve stimulation as a future treatment for ischemic stroke
- Effects of Noninvasive Facial Nerve Stimulation in the Dog Middle Cerebral Artery Occlusion Model of Ischemic Stroke
- Restored Brain Perfusion after Non-Invasive Stimulation of the Facial Nerve in a Canine Stroke Model
- Effect of pulsed magnetic stimulation of the facial nerve on cerebral blood flow
Vasospasm Reference Center
- Vasospasm and Delayed Consequences
- Vasospasm: Types, Causes & Symptoms
- Cerebral Vasospasm After Subarachnoid Hemorrhage
- Cerebral Vasospasm Following Subarachnoid Hemorrhage
- Utility of transcranial Doppler ultrasound for the integrative assessment of cerebrovascular function
- Treatment Options for Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage
- Cerebral Vasospasm in Traumatic Brain Injury